Latest Regulatory News

Lynas Rare Earths delivered record quarterly sales revenue of A$200.2 million in Q1 FY26, bolstered by a successful $932 million equity raise and strategic partnerships aimed at securing critical rare earth supply chains outside China.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.

Caravel Minerals has appointed Primero Group as its preferred EPCM firm and secured a $15 million loan to fund its Definitive Feasibility Study, marking significant progress toward a Final Investment Decision for the Caravel Copper Project.

FireFly Metals has reported exceptional drilling results at its Green Bay Copper-Gold Project, extending known mineralisation by over 650 metres and progressing key studies for an upscaled production restart.

Fluence Corporation reported a robust 72.9% revenue increase in Q3 2025, driven by a strategic pivot towards higher-margin Smart Product Solutions and recurring revenue streams. The company maintains its full-year guidance despite expecting to finish near the lower end.

Sparc Technologies has completed construction of a pioneering green hydrogen pilot plant and secured new patents, while its graphene additive trials show promising corrosion resistance results.

PhosCo has received a €1 million grant from the European Bank for Reconstruction and Development alongside a $1.1 million investment from its Managing Director, fueling optimisation efforts ahead of the Gasaat Phosphate Project’s bankable feasibility study.

Dubber Corporation Limited reported its first-ever positive net operating cashflow excluding exceptional items in Q1 FY26, supported by cost savings and a strong cash position. The company also expanded its partner network and targets operating cashflow breakeven this fiscal year.

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

CurveBeam AI has inked a decade-long exclusive partnership with a major Chinese medical device joint venture, unlocking rapid market entry and a $10 million capital boost to expand its weight bearing CT and AI solutions across Greater China.